Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1402.42 Billion KRW | 24.67% |
| 2022 | 1124.88 Billion KRW | 7.47% |
| 2021 | 1046.7 Billion KRW | 10.61% |
| 2020 | 946.33 Billion KRW | 18.09% |
| 2019 | 801.35 Billion KRW | 12.63% |
| 2018 | 711.49 Billion KRW | 5.06% |
| 2017 | 677.2 Billion KRW | 5.53% |
| 2016 | 641.69 Billion KRW | 11.35% |
| 2015 | 576.28 Billion KRW | 0.44% |
| 2014 | 573.75 Billion KRW | 9.92% |
| 2013 | 521.95 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1468.04 Billion KRW | 3.76% |
| 2024 Q1 | 1414.82 Billion KRW | 0.88% |
| 2023 Q2 | 1185.24 Billion KRW | 1.4% |
| 2023 Q1 | 1168.86 Billion KRW | 3.91% |
| 2023 FY | 1402.42 Billion KRW | 24.67% |
| 2023 Q4 | 1402.42 Billion KRW | 10.39% |
| 2023 Q3 | 1270.39 Billion KRW | 7.18% |
| 2022 Q3 | 1110.28 Billion KRW | 1.18% |
| 2022 Q2 | 1097.28 Billion KRW | 2.7% |
| 2022 FY | 1124.88 Billion KRW | 7.47% |
| 2022 Q1 | 1068.48 Billion KRW | 2.08% |
| 2022 Q4 | 1124.88 Billion KRW | 1.31% |
| 2021 Q1 | 941.49 Billion KRW | -0.51% |
| 2021 Q4 | 1046.7 Billion KRW | -3.09% |
| 2021 FY | 1046.7 Billion KRW | 10.61% |
| 2021 Q3 | 1080.04 Billion KRW | 14.06% |
| 2021 Q2 | 946.88 Billion KRW | 0.57% |
| 2020 Q2 | 887.6 Billion KRW | 6.95% |
| 2020 Q3 | 964.26 Billion KRW | 8.64% |
| 2020 FY | 946.33 Billion KRW | 18.09% |
| 2020 Q1 | 829.95 Billion KRW | 3.57% |
| 2020 Q4 | 946.33 Billion KRW | -1.86% |
| 2019 FY | 801.35 Billion KRW | 12.63% |
| 2019 Q1 | 722.38 Billion KRW | 1.53% |
| 2019 Q4 | 801.35 Billion KRW | 3.95% |
| 2019 Q3 | 770.9 Billion KRW | 3.03% |
| 2019 Q2 | 748.22 Billion KRW | 3.58% |
| 2018 Q2 | 686.73 Billion KRW | 1.45% |
| 2018 FY | 711.49 Billion KRW | 5.06% |
| 2018 Q4 | 711.49 Billion KRW | 3.93% |
| 2018 Q3 | 684.57 Billion KRW | -0.31% |
| 2018 Q1 | 676.95 Billion KRW | -0.04% |
| 2017 FY | 677.2 Billion KRW | 5.53% |
| 2017 Q4 | 677.2 Billion KRW | 0.0% |
| 2016 Q2 | 616.6 Billion KRW | 3.19% |
| 2016 Q1 | 597.56 Billion KRW | 3.69% |
| 2016 FY | 641.69 Billion KRW | 11.35% |
| 2016 Q3 | 626.96 Billion KRW | 1.68% |
| 2015 Q2 | 583.38 Billion KRW | -2.47% |
| 2015 Q4 | 576.28 Billion KRW | -2.05% |
| 2015 Q1 | 598.18 Billion KRW | 4.26% |
| 2015 Q3 | 588.33 Billion KRW | 0.85% |
| 2015 FY | 576.28 Billion KRW | 0.44% |
| 2014 Q2 | 554.68 Billion KRW | -1.32% |
| 2014 Q1 | 562.1 Billion KRW | 0.0% |
| 2014 Q3 | 563.68 Billion KRW | 1.62% |
| 2014 FY | 573.75 Billion KRW | 9.92% |
| 2014 Q4 | 573.75 Billion KRW | 1.79% |
| 2013 FY | 521.95 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -607.534% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 28.342% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | -59.912% |
| HANDOK Inc. | 790.33 Billion KRW | -77.446% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -721.961% |
| Yuhan Corporation | 2814.07 Billion KRW | 50.164% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | -6.631% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -1400.26% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 28.156% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -484.962% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -199.087% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -1119.786% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -492.871% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -302.55% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -607.534% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -234.557% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -180.612% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -137.943% |
| JW Holdings Corporation | 1176.26 Billion KRW | -19.227% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -129.432% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -117.418% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -300.598% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -810.425% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -278.339% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -187.78% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -607.534% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | -30.087% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 20.781% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -117.418% |
| Yuhan Corporation | 2814.07 Billion KRW | 50.164% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | -59.367% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -518.898% |
| Suheung Co., Ltd. | 993.73 Billion KRW | -41.127% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -117.418% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -233.99% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -199.114% |
| CKD Bio Corp. | 293.78 Billion KRW | -377.365% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -176.069% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -148.23% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -249.535% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -300.598% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 3.68% |
| Boryung Corporation | 922.36 Billion KRW | -52.048% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -216.96% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -199.087% |
| JW Lifescience Corporation | 255.83 Billion KRW | -448.174% |